Latus has refocused its core activity from oncology R&D to identify, promote and facilitate the evaluation of treatments for COVID-19. This not for profit project orchestrated by Latus will assess the effectiveness of the existing drugs Camostat and Nafamostat to fight the virus.

Latus established a collaboration with Ono Pharmaceuticals for drug provision and secured £1M from LifeArc to support clinical evaluation. Latus will now be supported by Cancer Research UK to implement their trial strategy and test the effectiveness of both drugs in treating COVID-19 infected individuals with the essential support of the University of Edinburgh.

Latus' SPIKE-1 trial: Camostat to be evaluated as a potential treatment for COVID-19

More Info >

Latus' SPIKE-2 trial: Nafamostat to be trialled as the most potent antiviral drug candidate

More Info >

Latus is delighted to announce its partnership with Cancer Research UK, LifeArc & University of Edinburgh

Our Story

The science behind coronavirus' invasion of human cells

SPIKE trials are designed to be

Because Camostat is an established drug

This means it is already cleared as safe to use, dramatically reducing lead times